Helsinn to co-support a satellite symposium on current and emerging treatments of Acute Myeloid Leukemia (AML) at 24th European Hematology Association (EHA) Congress

Ads

You May Also Like

Helix BioPharma Corp. Announces Fiscal 2018 Year-End Results

RICHMOND HILL, Ontario, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: ...

Progenics Pharmaceuticals Announces Third Quarter 2018 Financial Results And Business Update

AZEDRA® (iobenguane I 131) Approved by U.S. Food and Drug Administration (FDA)AZEDRA U.S. Launch Progressing ...